IS6555A - Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni - Google Patents
Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkniInfo
- Publication number
- IS6555A IS6555A IS6555A IS6555A IS6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A IS 6555 A IS6555 A IS 6555A
- Authority
- IS
- Iceland
- Prior art keywords
- treatment
- vascular damaging
- separate doses
- vasodilatory activity
- damaging agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0007740A GB0007740D0 (en) | 2000-03-31 | 2000-03-31 | Combination therapy |
GB0013928A GB0013928D0 (en) | 2000-06-08 | 2000-06-08 | Methods of treatment |
GB0014904A GB0014904D0 (en) | 2000-06-20 | 2000-06-20 | Methods of treatment |
PCT/GB2001/001329 WO2001074369A1 (en) | 2000-03-31 | 2001-03-27 | Divided dose therapies with vascular damaging activity |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6555A true IS6555A (is) | 2002-10-18 |
Family
ID=27255635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6555A IS6555A (is) | 2000-03-31 | 2002-09-19 | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030055024A1 (is) |
EP (1) | EP1272200B1 (is) |
JP (1) | JP2003528921A (is) |
KR (1) | KR20020084267A (is) |
CN (1) | CN1422157A (is) |
AT (1) | ATE298240T1 (is) |
AU (2) | AU2001242586B2 (is) |
BR (1) | BR0109671A (is) |
CA (1) | CA2402078A1 (is) |
CZ (1) | CZ20023231A3 (is) |
DE (1) | DE60111622T2 (is) |
EE (1) | EE200200549A (is) |
ES (1) | ES2243466T3 (is) |
HU (1) | HUP0300576A3 (is) |
IL (1) | IL151627A0 (is) |
IS (1) | IS6555A (is) |
MX (1) | MXPA02009603A (is) |
NO (1) | NO20024683L (is) |
NZ (1) | NZ534190A (is) |
PL (1) | PL357282A1 (is) |
PT (1) | PT1272200E (is) |
SK (1) | SK13902002A3 (is) |
WO (1) | WO2001074369A1 (is) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200200565A (et) | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
FR2848212B1 (fr) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation |
BRPI0411567A (pt) * | 2003-06-18 | 2006-08-01 | Angiogene Pharm Ltd | uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente |
GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL67646A0 (en) * | 1982-01-15 | 1983-05-15 | Lilly Co Eli | Ascorbic acid ethers and related compounds |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
WO1991006668A1 (en) * | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
ES2064101T3 (es) * | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
JPH06503095A (ja) * | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
JPH11228594A (ja) * | 1998-02-16 | 1999-08-24 | Meiji Milk Prod Co Ltd | 新規プロゲステロン化合物 |
EP1189611B1 (en) * | 1999-06-14 | 2006-05-03 | Cancer Research Technology Limited | Cancer therapy |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
-
2001
- 2001-03-27 CZ CZ20023231A patent/CZ20023231A3/cs unknown
- 2001-03-27 EP EP01915495A patent/EP1272200B1/en not_active Expired - Lifetime
- 2001-03-27 PT PT01915495T patent/PT1272200E/pt unknown
- 2001-03-27 HU HU0300576A patent/HUP0300576A3/hu unknown
- 2001-03-27 CN CN01807663A patent/CN1422157A/zh active Pending
- 2001-03-27 CA CA002402078A patent/CA2402078A1/en not_active Abandoned
- 2001-03-27 US US10/239,898 patent/US20030055024A1/en not_active Abandoned
- 2001-03-27 NZ NZ534190A patent/NZ534190A/en unknown
- 2001-03-27 MX MXPA02009603A patent/MXPA02009603A/es unknown
- 2001-03-27 ES ES01915495T patent/ES2243466T3/es not_active Expired - Lifetime
- 2001-03-27 AT AT01915495T patent/ATE298240T1/de not_active IP Right Cessation
- 2001-03-27 IL IL15162701A patent/IL151627A0/xx unknown
- 2001-03-27 SK SK1390-2002A patent/SK13902002A3/sk unknown
- 2001-03-27 PL PL01357282A patent/PL357282A1/xx not_active Application Discontinuation
- 2001-03-27 EE EEP200200549A patent/EE200200549A/xx unknown
- 2001-03-27 AU AU2001242586A patent/AU2001242586B2/en not_active Ceased
- 2001-03-27 KR KR1020027012915A patent/KR20020084267A/ko not_active Application Discontinuation
- 2001-03-27 JP JP2001572112A patent/JP2003528921A/ja active Pending
- 2001-03-27 BR BR0109671-0A patent/BR0109671A/pt not_active IP Right Cessation
- 2001-03-27 WO PCT/GB2001/001329 patent/WO2001074369A1/en not_active Application Discontinuation
- 2001-03-27 DE DE60111622T patent/DE60111622T2/de not_active Expired - Fee Related
- 2001-03-27 AU AU4258601A patent/AU4258601A/xx active Pending
-
2002
- 2002-09-19 IS IS6555A patent/IS6555A/is unknown
- 2002-09-30 NO NO20024683A patent/NO20024683L/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003528921A (ja) | 2003-09-30 |
US20030055024A1 (en) | 2003-03-20 |
MXPA02009603A (es) | 2004-05-14 |
DE60111622D1 (de) | 2005-07-28 |
PT1272200E (pt) | 2005-09-30 |
CA2402078A1 (en) | 2001-10-11 |
IL151627A0 (en) | 2003-04-10 |
ES2243466T3 (es) | 2005-12-01 |
AU4258601A (en) | 2001-10-15 |
DE60111622T2 (de) | 2006-05-18 |
ATE298240T1 (de) | 2005-07-15 |
AU2001242586B2 (en) | 2004-12-16 |
WO2001074369A1 (en) | 2001-10-11 |
PL357282A1 (en) | 2004-07-26 |
BR0109671A (pt) | 2003-02-04 |
KR20020084267A (ko) | 2002-11-04 |
HUP0300576A2 (hu) | 2003-07-28 |
NO20024683D0 (no) | 2002-09-30 |
NO20024683L (no) | 2002-10-15 |
SK13902002A3 (sk) | 2003-05-02 |
CN1422157A (zh) | 2003-06-04 |
CZ20023231A3 (cs) | 2003-01-15 |
NZ534190A (en) | 2007-05-31 |
EP1272200B1 (en) | 2005-06-22 |
EP1272200A1 (en) | 2003-01-08 |
EE200200549A (et) | 2004-02-16 |
HUP0300576A3 (en) | 2005-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1933833E (pt) | Terapia para o tratamento da bexiga superactiva | |
BG108443A (en) | Substituted oxazoliidinones for combinational therapy | |
NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
IL151628A0 (en) | Combination therapies with vascular damaging activity | |
MX2020010322A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
DE60138572D1 (de) | Methoden und pharmazeutische zusammensetzungen zur wundheilung | |
SE0102440D0 (sv) | New compound | |
MXPA06001286A (es) | Metodos para tratar la inflamacion y enfermedades asociadas con la inflamacion con una estatina y un eter. | |
DE60026491D1 (de) | Melagatran zur behandlung von entzündungen | |
IS6555A (is) | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni | |
ATE502637T1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
HRPK20040328B3 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
GR1004434B (el) | Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων | |
DE602006016168D1 (de) | 1,3,5-triazepin-dionen zur Behandlung von Malaria | |
MXPA02007454A (es) | Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor. |